Welcome to our dedicated page for Zomedica SEC filings (Ticker: ZOM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zomedica Corp. (ZOM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, annual and quarterly reports, and exhibits referenced in press releases. Zomedica identifies itself as an animal health company focused on point-of-care diagnostic and therapeutic device products for equine and companion animals, and its filings offer additional detail on this business.
For example, an 8-K dated August 6, 2025 notes that Zomedica issued a press release announcing financial results for the quarter ended June 30, 2025 and furnished that release as an exhibit. Filings such as 10-K annual reports and 10-Q quarterly reports, when available, typically include information on product platforms like TRUFORMA, TRUVIEW, PulseVet, Assisi, VETGuardian, and VETIGEL, along with segment disclosures for diagnostics, therapeutic devices, consumables, capital equipment, and Development Services.
Through this page, users can review how Zomedica discusses its intellectual property portfolio, which it reports includes numerous U.S. and international patents and trademarks, and how it describes risks related to product development, commercialization, regulatory approvals, supply chain, and strategic partnerships. Insider transaction reports on Form 4, when filed, can help investors monitor equity activity by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, helping readers quickly understand topics such as revenue composition, liquidity, and business strategy without reading every page. Real-time updates from EDGAR mean that new Zomedica filings appear promptly, while AI insights on 10-Ks, 10-Qs, 8-Ks, and other forms can assist investors, analysts, and interested veterinary professionals in interpreting the company’s regulatory reporting.
Kevin Klass, Senior Vice President, Sales at Zomedica Corp., reported purchases of 60,723 shares on 08/11/2025 at $0.04, and 250,000 and 745,341 shares on 08/12/2025 at $0.04. Following these reported transactions, his beneficial ownership is shown sequentially as 4,260,753, 4,510,753 and 5,256,094 shares.
Zomedica Corp. reporting person Kevin Klass, Sr. Vice President of Sales, reported purchases on 08/11/2025 totaling 500,000 common shares in two transactions: 250,000 shares at $0.038 and 250,000 shares at $0.04. The filings show direct beneficial ownership rising to 4,200,030 shares. The Form 4 is signed on 08/12/2025. No derivative transactions are reported.
Kevin Klass, Senior Vice President of Sales at Zomedica Corp., reported acquiring 500,000 shares of common stock on 08/08/2025 at $0.04 per share under transaction code P (pursuant to a written plan). Following this transaction his reported beneficial ownership is 3,700,030 shares, held directly.